Clonal hematopoiesis study reveals clinical significance in lymphoma patients


A study investigating the prevalence and significance of clonal hematopoiesis of indeterminate potential (CHIP) and involving several members of Clinical Genomics Uppsala (CGU) was published in the American Journal of Hematology.

Several studies have previously reported that CHIP (the presence of somatically mutated genes in the blood of healthy individuals) is associated with increased risk of development of myeloid neoplasms in lymphoma patients. In the article from CGU, the prevalence of CHIP and its impact on treatment outcome in lymphoma patients was investigated.

The study revealed that for lymphoma patients treated with standard chemo-immunotherapy, the presence of CHIP was associated with an impaired clinical outcome. These patients had significantly worse progression free survival, overall survival and lymphoma specific survival. The results may have clinical implications for these patients, in particular with regard to the use of targeted therapy.

From CGU, Rose-Marie Amini, Lucia Cavelier and Tatjana Pandzic were involved in the study.

You can read the article here.

Last modified: 2024-02-23